183 related articles for article (PubMed ID: 29322496)
1. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Oji Y; Inoue M; Takeda Y; Hosen N; Shintani Y; Kawakami M; Harada T; Murakami Y; Iwai M; Fukuda M; Nishida S; Nakata J; Nakae Y; Takashima S; Shirakata T; Nakajima H; Hasegawa K; Kida H; Kijima T; Morimoto S; Fujiki F; Tsuboi A; Morii E; Morita S; Sakamoto J; Kumanogoh A; Oka Y; Okumura M; Sugiyama H
Int J Cancer; 2018 Jun; 142(11):2375-2382. PubMed ID: 29322496
[TBL] [Abstract][Full Text] [Related]
2. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
5. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
[TBL] [Abstract][Full Text] [Related]
7. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
8. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
[TBL] [Abstract][Full Text] [Related]
10. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
[TBL] [Abstract][Full Text] [Related]
12. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
13. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
14. The tumor doubling time is a useful parameter for predicting the histological type of thymic epithelial tumors.
Fukumoto K; Fukui T; Kawaguchi K; Nakamura S; Hakiri S; Ozeki N; Mori S; Goto M; Hashimoto K; Tateyama H; Yokoi K
Surg Today; 2019 Aug; 49(8):656-660. PubMed ID: 31134370
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases.
Wang CL; Zhao YZ; Zhang Q; Zeng WQ; Jia TY; Zhu L; Fang WT; Fu XL
Anticancer Drugs; 2023 Aug; 34(7):852-856. PubMed ID: 36729892
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
[TBL] [Abstract][Full Text] [Related]
19. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
[TBL] [Abstract][Full Text] [Related]
20. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience.
Yellin A; Simansky DA; Ben-Avi R; Perelman M; Zeitlin N; Refaely Y; Ben-Nun A
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):83-7; discussion 87-9. PubMed ID: 23111024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
